Citi analyst Patrick Donnelly downgraded Bio-Rad to Neutral from Buy with a price target of $365, down from $400. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BIO: 5 Best Healthcare Stocks to Buy in March 2024, According to Analysts Bio-Rad Laboratories Announces New CFO Roop K. Lakkaraju Bio-Rad appoints Roop Lakkaraju EVP, CFO Bio-Rad Laboratories Reports Strong Sartorius AG Financials Early notable gainers among liquid option names on February 16th